A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Thyroid cancer
- Focus Pharmacodynamics
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Planned initiation date changed from 1 May 2018 to 1 Aug 2018.